Mustafa Ozguroglu

Papers authored by Mustafa Ozguroglu

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

2019 R. S. Herbst, F. de Marinis, G. Giaccone, N. Reinmuth, A. Vergnenegre, C. H. Barrios, M. Morise, E. Felip, Z. Andric, S. Geater, M. Ozguroglu

, S. Mocci, M. McCleland, W. Zou, I. Enquist and 5 other authors

Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study

Upload

E. Grande, M. Galsky, J. A. Arranz Arija, M. De Santis, I. D. Davis, U. F. F. De Giorgi, M. Mencinger, E. Kikuchi, X. Garcia del Muro, M. Gumus, M. Ozguroglu

, A. Rezazadeh Kalebasty, S. H. Park, B. Y. Alekseev, F. A. B. Schutz and 5 other authors

IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

Upload

Fabrice Barlesi, Mustafa Ozguroglu

, Johan Vansteenkiste, David Spigel, James Yang, Hidenobu Ishii, Marina Garassino, Filippo de Marinis, Aleksandra Szczesna, Andreas Polychronis, Ruchan Uslu, Maciej Krzakowski, Jong-Seok Lee, Luana Calabro, Osvaldo Aren Frontera and 4 other authors

2-year follow-up from JAVELIN Lung 200, an open-label, randomized, phase 3 study of avelumab vs docetaxel in patients with platinum-treated advanced non-small cell lung cancer (NSCLC)

Upload

M. Ozguroglu

, J. W. Goldman, N. Reinmuth, Y. Chen, M. Dvorkin, D. Trukhin, G. Statsenko, K. Hotta, J. H. Ji, M. J. Hochmair, O. Voitko, L. Havel, A. Poltoratskiy, G. Losonczy, F. Verderame and 5 other authors

First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN

Upload

L. Paz-Ares, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, Mj Hochmair, M. Özgüroğlu

, Jh Ji, O. Voitko

PL02. 11 Overall survival with durvalumab plus etoposide-platinum in first-line extensive-stage SCLC: results from the CASPIAN study

Upload

K. Chi, S. Mundle, Y. Luna, S. Li, A. Protheroe, S. Feyerabend, D. Ye, M. Ozguroglu

, B. Alekseev, A. Rodriguez-Antolin, N. Matsubara, L. Fein, N. Tran, G. Sulur, K. Fizaz and 1 other authors

Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT)

Upload

A. S. Merseburger, S. Chowdhury, N. Agarwal, A. Bjartell, B. H. Chung, A. J. Pereira de Santana Gomes, R. W. Given, A. J. Soto, M. Ozguroglu

, H. Uemura, D. W. Ye, K. Deprince, Naini, J. Li, S. Cheng and 5 other authors

TITAN, a phase 3 study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT)

Upload

This paper is made freely available by the publisher.

2018 Hideyuki Akaza, Giuseppe Procopio, Choosak Pripatnanont, Gaetano Facchini

, Sergio Fava, Duncan Wheatley, Kwong Chuen Leung, Mohammad Butt, Alberto Silva, Liliana Castillo, Vasilios Karavasilis, Ayse Ӧzatılgan, Simon Hitier, Evelyne B. Ecstein-Fraisse, Mustafa Ӧzgüroḡlu

Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Fabrice Barlesi, Johan Vansteenkiste, David Spigel, Hidenobu Ishii, Marina Garassino, Filippo de Marinis, Mustafa Özgüroğlu

, Maciej Krzakowski, Aleksandra Szczesna, Jong-Seok Lee, Andreas Polychronis, Luana Calabrò, Osvaldo Arén Frontera, Ruchan Uslu, Barbara Ellers-Lenz and 3 other authors

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Upload

M. Socinski, M. Özgüroğlu

, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, J. Gray, K. Park, M. Vincent, F. Perrone, L. Poole, C. Wadsworth, P. Dennis, S. Antonia

P1.16-04 Outcomes of Patients <70 or ≥70 Years of Age in PACIFIC

Upload

S. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, T. Kurata, A. Chiappori, K. H. Lee, M. De Wit, B. C. Cho, M. Bourhaba, X. Quantin, T. Tokito, T. Mekhail and 17 other authors

PL02.01 Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC

Upload

Distributing this paper is prohibited by the publisher

Guy Jerusalem, Richard H. de Boer, Sara Hurvitz, Denise A. Yardley, Elena Kovalenko, Bent Ejlertsen, Sibel Blau, Mustafa Özgüroglu

, László Landherr, Marianne Ewertz, Tetiana Taran, Jenna Fan, Florence Noel-Baron, Anne-Laure Louveau, Howard Burris

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer

Upload

Corinne Faivre-Finn, Dr R. Spigel, S. Senan, Cj J. Langer, D. Raben, B. Perez, M. Özgüroğlu

, D. Daniel, R. Hui, S. Murakami, A. Villegas, L. Paz-Ares, D. Vicente, L. Poole, C. Wadsworth and 2 other authors

Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC

Upload

D. Spigel, J. Vansteenkiste, M. Reck, H. Wakelee, M. Özgüroğlu

, D. Daniel, A. Villegas, D. Vicente, R. Hui, S. Murakami, L. Paz-Ares, L. Poole, C. Wadsworth, P. Dennis, S. Antonia

P1.16-05 Effect of Induction Chemotherapy in the PACIFIC Study

Upload

J. Vansteenkiste, J. Naidoo, C. Faivre-Finn, M. Özgüroğlu

, A. Villegas, D. Daniel, S. Murakami, R. Hui, K. Lee, B. C. Cho, K. Kubota, L. Poole, C. Wadsworth, P. Dennis, S. Antonia

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT

Upload

A. Spira, D. Planchard, B. C. Cho, M. Özgüroğlu

, D. Daniel, A. Villegas, D. Vicente, R. Hui, S. Murakami, L. Paz-Ares, A. Boothman, L. Poole, C. Wadsworth, P. Dennis, S. Antonia

P1.16-06 Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%

Upload

Cc-C. Lin, M. Taylor, V. Boni, Pf F. Brunsvig, P. Garrido Lopez, Sl L. Geater, S. Salvagni, S. Ponce Aix, P. A. Ascierto, A. Fasolo, M. Özgüroğlu

, A. Sezer, V. Sriuranpong, D. M. Kowalski, J. E. Faris and 5 other authors

Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer

Upload

F. Barlesi, J. Vansteenkiste, D. Spigel, H. Ishii, M. Garassino, F. De Marinis, M. Özgüroğlu

, A. Szczesna, A. Polychronis, R. Uslu, M. Krzakowski, J. Lee, L. Calabro, O. Frontera, B. Ellers-Lenz and 3 other authors

OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial

Upload

Antoine Angelergues, Eleni Efstathiou, Revekka Gyftaki, Piotr Jan Wysocki, Nuria Lainez, Iria Gonzalez, Daniel E. Castellano, Mustafa Ozguroglu

, Iciar Garcia Carbonero, Aude Flechon, Pablo Borrega, Aline Guillot, Begona Campos Balea, Sylvestre Le Moulec, Emilio Esteban and 6 other authors

Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents

Upload

Melanie Royce, Thomas Bachelot, Cristian Villanueva, Mustafa Özgüroglu

, Sergio J. Azevedo, Felipe Melo Cruz, Marc Debled, Roberto Hegg, Tatsuya Toyama, Carla Falkson, Joon Jeong, Vichien Srimuninnimit, William J. Gradishar, Christina Arce, Antonia Ridolfi and 2 other authors

Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

Papers authored by Mustafa Ozguroglu